Adage Capital Partners GP L.L.C. Boosts Position in Immunome, Inc. (NASDAQ:IMNM)

Adage Capital Partners GP L.L.C. lifted its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 127.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 500,000 shares of the company's stock after buying an additional 280,000 shares during the period. Adage Capital Partners GP L.L.C. owned about 0.63% of Immunome worth $5,310,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in IMNM. KLP Kapitalforvaltning AS purchased a new stake in Immunome during the fourth quarter valued at approximately $75,000. AlphaQuest LLC raised its holdings in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares during the period. Tower Research Capital LLC TRC lifted its position in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after buying an additional 7,129 shares during the last quarter. Stoneridge Investment Partners LLC purchased a new position in Immunome during the fourth quarter worth $123,000. Finally, Teacher Retirement System of Texas bought a new position in Immunome during the fourth quarter valued at $124,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall bought 137,100 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the purchase, the chief executive officer now directly owns 806,736 shares in the company, valued at $5,881,105.44. This represents a 20.47 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the firm's stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $8.21 per share, with a total value of $57,470.00. Following the completion of the purchase, the director now owns 23,615 shares of the company's stock, valued at $193,879.15. The trade was a 42.13 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 156,400 shares of company stock valued at $1,160,495. Corporate insiders own 8.60% of the company's stock.

Immunome Stock Down 0.1 %

NASDAQ:IMNM traded down $0.01 during mid-day trading on Friday, reaching $8.85. The company's stock had a trading volume of 551,017 shares, compared to its average volume of 904,880. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $16.81. The stock has a fifty day moving average of $7.90 and a 200-day moving average of $10.08. The firm has a market capitalization of $770.06 million, a PE ratio of -1.09 and a beta of 2.05.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on IMNM. Stephens reiterated an "overweight" rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Guggenheim decreased their price target on Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective on the stock. Wedbush reiterated an "outperform" rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Lake Street Capital assumed coverage on shares of Immunome in a report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price target on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $25.33.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.